Lo et al. utilized wild-type, human gastric organoids to establish the first forward, genetic, human ARID1A-deficient oncogenic transformation model using CRISPR/Cas9-engineered ARID1A depletion alongside a mutation of TP53, which is a co-occurring tumor suppressor. The gene discussed is ARID1A; the disease is neoplasm.